Valneva Shares: Analysts See Substantial Upside Potential

Despite recent market jitters affecting investor sentiment, the underlying financial performance of French vaccine specialist Valneva tells a different story. While the company’s share price has experienced a significant downturn, its recently released nine-month results for 2025 were robust, with management reaffirming its full-year outlook even amidst a challenging operating climate. Adding a jolt of optimism to this gloomy market atmosphere, a prominent analyst firm has issued a striking assessment, suggesting the stock’s potential could far exceed its current trading level.

Analyst Confidence Clashes with Market Pessimism

The perspective from investment bank Stifel provides a compelling counter-narrative to the current share price weakness. The firm has reiterated its “Buy” recommendation, attaching a price target of €9.50. When measured against the recent share price of approximately €3.75, this projection implies a potential doubling of the company’s market valuation. This bullish stance is rooted not in the present-day business alone but in the future promise of Valneva’s Lyme disease vaccine candidate, VLA15. Analysts attribute a value of €7 per share to this single pipeline asset, indicating that the market is heavily discounting its potential success.

Operational Strength Provides a Solid Foundation

Financially, Valneva appears to be on stable ground. The company reported a healthy increase in revenue for the first three quarters of 2025, climbing to €127.0 million from €116.6 million in the prior-year period. A key growth driver was the travel vaccine IXIARO, which posted a 12.5% sales increase, providing crucial cash flow to fund ongoing research initiatives.

Should investors sell immediately? Or is it worth buying Valneva?

Further reinforcing its stability, the company’s management confirmed its financial guidance for the full year. The core takeaways from the operational update are clear:

• Revenue Growth: Sales advanced to €127.0 million.
• Strong Liquidity: The company holds a solid cash position of €143.5 million.
• Pipeline Focus: The confirmed financial runway into 2027 supports the continued development of key R&D projects.

The Pivotal Moment Awaits in 2026

The technical picture of the stock, however, has yet to reflect this fundamental and analytical confidence. With a Relative Strength Index (RSI) reading of 18.9, the shares are deep in oversold territory, a condition that often signals an exaggerated downward move. This recent sell-off has unsettled many shareholders, but for those focused on the long-term, the key milestone is now clearly on the horizon for 2026.

The anticipated results from the pivotal Phase 3 “VALOR” clinical study for the VLA15 Lyme disease vaccine are expected that year. Positive data from this trial are seen as the potential catalyst for a major re-rating of the stock. Until then, Valneva shares represent a dynamic investment proposition, balancing current operational solidity against the high-stakes potential of a breakthrough from its development pipeline.